Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2a Study of an Anti-LOXL2 Monoclonal Antibody (GS-6624) in HIV and/or Hepatitis C- Infected Subjects With Liver Fibrosis

NCT01707472 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT01707472
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01707472 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2a Study of an Anti-LOXL2 Monoclonal Antibody (GS-6624) in HIV and/or Hepatitis C- Infected Subjects With Liver Fibrosis
Lead sponsor
Gilead Sciences
Phase
Phase 2
Overall status
Completed
Start date
October 4, 2012
Completion date
October 17, 2014
Enrollment
18 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hepatitis c, hiv, hiv/hcv co-infection, liver fibrosis